Combination therapy with BRAF and MEK inhibitors significantly improves survival in BRAF mutated melanoma patients but is unable to prevent disease recurrence due to the emergence of drug resistance. Cancer stem cells (CSCs) have been involved in these long-term treatment failures. We previously reported in lung cancer that CSCs maintenance is due to altered lipid metabolism and dependent upon Stearoyl-CoA-desaturase (SCD1)-mediated upregulation of YAP and TAZ. On this ground, we investigated the role of SCD1 in melanoma CSCs.
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma / Pisanu, Maria Elena; Maugeri-Saccà, Marcello; Fattore, Luigi; Bruschini, Sara; De Vitis, Claudia; Tabbì, Eugenio; Bellei, Barbara; Migliano, Emilia; Kovacs, Daniela; Camera, Emanuela; Picardo, Mauro; Jakopin, Ziga; Cippitelli, Claudia; Bartolazzi, Armando; Raffa, Salvatore; Torrisi, Maria Rosaria; Fulciniti, Franco; Ascierto, Paolo A; Ciliberto, Gennaro; Mancini, Rita. - In: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. - ISSN 1756-9966. - 37:1(2018), pp. 1-17. [10.1186/s13046-018-0989-7]
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
Pisanu, Maria ElenaPrimo
Writing – Review & Editing
;Fattore, LuigiMethodology
;Bruschini, Sara;De Vitis, ClaudiaMethodology
;Cippitelli, ClaudiaMethodology
;Bartolazzi, ArmandoValidation
;Raffa, SalvatoreMethodology
;Torrisi, Maria Rosaria;Mancini, Rita
Ultimo
Writing – Original Draft Preparation
2018
Abstract
Combination therapy with BRAF and MEK inhibitors significantly improves survival in BRAF mutated melanoma patients but is unable to prevent disease recurrence due to the emergence of drug resistance. Cancer stem cells (CSCs) have been involved in these long-term treatment failures. We previously reported in lung cancer that CSCs maintenance is due to altered lipid metabolism and dependent upon Stearoyl-CoA-desaturase (SCD1)-mediated upregulation of YAP and TAZ. On this ground, we investigated the role of SCD1 in melanoma CSCs.| File | Dimensione | Formato | |
|---|---|---|---|
|
Pisanu_Inhibition_2018.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
5.5 MB
Formato
Adobe PDF
|
5.5 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
